Gilead Sciences Valuation

Gilead Sciences Inc retains regular Real Value of USD81.63 per share. The prevalent price of the corporation is USD71.92. At this time the corporation appears to be under valued. Macroaxis calculates value of Gilead Sciences Inc from evaluating the corporation fundamentals such as Current Valuation of 6.82B, Return On Asset of 20.23% and Return On Equity of 72.25% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.

Gilead Science took a bad hit when their bet on a medical trial failed.  Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead.  Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio.  For that matter, by any matrix, the stock is cheap and should go higher.  

Valuation Drivers Correlation

Selected Gilead Sciences Inc Valuation Data Over Time

Net Income Per Employee    Enterprise Value    Market Capitalization    
Investment Horizon     30 Days    Login   to change
Gilead Sciences Inc is rated # 3 in price to sales category among related companies. It is one of the top stocks in price to book category among related companies fabricating about  1.30  of Price to Book per Price to Sales.
Under Valued
June 29, 2017
71.92
Market Value
Downside upside
81.63
Real Value
Target Price Odds
 Above  Below  
85.53
Upside
Upside upside
Gilead Sciences is not too risky asset. Calculation of real value of Gilead Sciences Inc is based on 1 month time horizon. Increasing Gilead Sciences Inc time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Recommendations

Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
93.29Buy14Odds
Gilead Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  

Tax Efficiency

Gilead Sciences Inc Tax Efficiency History

Tax Efficiency

Market Capitalization

Gilead Sciences Market Capitalization Analysis
Gilead Sciences Inc is one of the top stocks in market capitalization category among related companies. Market capitalization of Pharmaceuticals And Biosciences industry is currently estimated at about 322.04 Billion. Gilead Sciences totals roughly 92.33 Billion in market capitalization claiming about 29% of equities listed under Pharmaceuticals And Biosciences industry.
Capitalization  Total debt  Workforce  Valuation  Revenue

Revenue

Gilead Sciences Inc Revenue
Based on latest financial disclosure Gilead Sciences Inc reported 29.1 B of revenue. This is 347.7% higher than that of the Healthcare sector, and significantly higher than that of Pharmaceuticals And Biosciences industry, The Revenue for all stocks is 195.53% lower than the firm.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.